| Title: |
Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort. |
| Authors: |
Truchetet, Marie-Elise; Drumez, Elodie; Barnetche, Thomas; Martin, Claire; Devaux, Mathilde; Goulenok, Tiphaine; Maria, Alexandre; Schmidt, Jean; Ait-Abdallah, Nassim; Melki, Isabelle; Hachulla, Eric; Richez, Christophe |
| Contributors: |
Université de Lille; CHU Lille; Service de Rhumatologie CHU Pellegrin; Service de Biostatistiques CHRU Lille; METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694; Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS Poissy; AP-HP - Hôpital Bichat - Claude Bernard Paris; Hôpital Saint Eloi CHU Montpellier; CHU Amiens-Picardie; Recherche clinique appliquée à l'hématologie (EA_3518); Hôpital Robert Debré Paris; Imagine - Institut des maladies génétiques IMAGINE - U1163; Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France CeRAINO; Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286 |
| Publication Year: |
2024 |
| Collection: |
LillOA (Lille Open Archive - Université de Lille) |
| Subject Terms: |
COVID-19; Immune System Diseases; Outcome Assessment; Health Care |
| Description: |
Background Patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) receiving mycophenolic acid (MPA) may have a less favourable outcome from COVID-19 infection. Our aim was to investigate whether MPA treatment is associated with severe infection and/or death. Methods IRMD patients with and without MPA treatment with highly suspected/confirmed COVID-19 were included in this observational multicentre study. The primary outcome was death rate from COVID-19 with secondary objectives to determine the severity of infection and length of hospital stay. Outcome comparisons were made using regression models with and without adjustment on prespecified confounding factors. ORs, sub-HR (sHR) and 95% CIs were calculated using patients not treated with MPA as a reference group. Results Of the 1977 patients, 1928 were not treated with MPA (393 were MPA eligible), and 49 patients were treated with MPA. MPA-treated patients had more severe disease, longer hospital stays and higher death rate from COVID-19 than non-MPA patients (OR 8.02 (95% CI 3.35 to 19.20), p |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf |
| Language: |
English |
| Relation: |
RMD Open : Rheumatic & Musculoskeletal Diseases; RMD Open; http://hdl.handle.net/20.500.12210/89988 |
| Availability: |
https://hdl.handle.net/20.500.12210/89988 |
| Rights: |
Attribution-NonCommercial 3.0 United States ; info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.334F6E3E |
| Database: |
BASE |